Keeping pace with the times and embracing change—Ruihe Pharmaceutical Group’s 2026 Mid-Year Work Plan Meeting Convened Successfully.
Chairman Xiong Yigang provided a thorough analysis of the new landscape confronting the pharmaceutical industry and set forth strategic priorities for the second half of the year. He emphasized the need to firmly consolidate the company’s core business by simultaneously pursuing revenue growth and cost efficiency, while accelerating the development of a second growth trajectory and concentrating resources on establishing benchmark markets at the provincial level. He further underscored the importance of strengthening end-to-end process management across all operations, instituting a monthly review mechanism, and enhancing our capacity for rapid response—adopting a pragmatic, results‑driven approach to navigate industry cycles and secure new opportunities for growth.
2026 7 month 21 Day, Guizhou Ruihe Pharmaceutical Co., Ltd. 2026 The semi-annual work summary meeting was held in the company’s conference room. The meeting was chaired by General Manager Zhao Yun, and Chairman Xiong Yigang attended and delivered an important address.
At the meeting, Chairman Xiong Yigang provided an in-depth analysis of the new landscape confronting the pharmaceutical industry and set forth strategic priorities for the second half of the year. He emphasized the need to firmly consolidate the company’s core business by simultaneously pursuing revenue growth and cost efficiency, while accelerating the development of a second growth trajectory and concentrating superior resources on establishing benchmark markets at the provincial level. He further underscored the importance of strengthening end-to-end process control across all operations, instituting a monthly review mechanism, and enhancing the organization’s capacity for rapid response—ensuring that, through a pragmatic and results-oriented approach, the company can navigate industry cycles and unlock new opportunities for growth.
Subsequently, the heads of each department reported in turn on their progress for the first half of the year and outlined key initiatives for the second half, conducting a comprehensive review of business developments and articulating clear priorities for the period ahead.
In his concluding remarks, General Manager Zhao Yun stated that in the second half of the year, the company must confront challenges head-on and maintain a clear-eyed approach, focusing on four core priorities: First, align efforts to achieve both sales volume and profit targets, deepen compliance management, accelerate channel development, and ensure the successful implementation of new product launches; the Medical Marketing Department must provide full support to frontline sales teams. Second, tighten cost control, rigorously review all expense items, and rationally optimize the workforce‑cost structure. Third, systematically upgrade the compliance management framework, transforming compliance capabilities into a sustainable competitive advantage. Fourth, strengthen a holistic service mindset, proactively deliver services at the earliest possible stage, and enhance cross‑functional collaboration.
Finally, General Manager Zhao Yun called on all attendees to remain confident, tackle challenges head-on, create value through unwavering dedication, and unite as one to pool our strengths, thereby ensuring the successful achievement of our annual objectives.
Keywords: